MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

Jean‐Jacques Kiladjian, Claire Harrison, Ruben A. Mesa, Haifa Kathrin Al‐Ali, John Mascarenhas, Fabián Sanabria, Julie Vienne Bürki, Bourras‐Rezki Bengoudifa, Francesco Passamonti